Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | CA9 | Q16790 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3754562 | 0.89 | CYP2C9 (0.36) | CA1CA2CA9 | |
| SCHEMBL3766342 | 0.84 | CA1 (0.39) | CA1CA2CA9 | |
| SCHEMBL1156126 | 0.76 | — | — | |
| SCHEMBL3765248 | 0.73 | LMNA (0.36) | CA1CA2CA9 | |
| SCHEMBL61667 | 0.70 | CA1 (0.47) | CA1CA2CA9 | |
| SCHEMBL5659493 | 0.68 | KEAP1 (0.34) | — | |
| SCHEMBL845242 | 0.67 | CA1 (0.34) | CA1CA2CA9 | |
| SCHEMBL5297954 | 0.67 | BRD4 (0.34) | — | |
| SCHEMBL10443651 | 0.64 | CA9 (0.50) | CA1CA2CA9 | |
| SCHEMBL1450521 | 0.64 | CA2 (0.33) | CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8076488-B2 | Antiproliferative agents; angiogenesis inhibitors; anticancer agents | BAYER HEALTHCARE LLC (US) | 2011-12-13 | — | — | US | claimed |
| JP-4658037-B2 | — | — | 2011-03-23 | — | — | JP | claimed |
| EP-1599467-B1 | NOVEL CYANOPYRIDINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER AND OTHER DISORDERS | BAYER HEALTHCARE LLC (US) | 2010-05-19 | — | — | EP | claimed |
| JP-2006519264-A | — | — | 2006-08-24 | — | — | JP | claimed |
| EP-1599467-A1 | NOVEL CYANOPYRIDINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER AND OTHER DISORDERS | Bayer Pharmaceuticals Corporation (US) | 2005-11-30 | — | — | EP | claimed |
| US-20050038031-A1 | Novel bicyclic urea derivatives useful in the treatment of cancer and other disorders | BAYER HEALTHCARE LLC | 2005-02-17 | — | — | US | claimed |
| US-20040235829-A1 | Novel cyanopyridine derivatives useful in the treatment of cancer and other disorders | BAYER HEALTHCARE LLC | 2004-11-25 | — | — | US | claimed |
| WO-2004078747-A1 | NOVEL CYANOPYRIDINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER AND OTHER DISORDERS | BAYER PHARMACEUTICALS CORPORATION (US) | 2004-09-16 | — | — | WO | claimed |
| CN-113149883-B | Process for preparing pyrrole compounds | 武田药品工业株式会社 | 2024-04-02 | — | — | CN | disclosed |
| US-20230143246-A1 | LIQUID PREPARATIONS OF AMINES AND ORGANIC ACIDS STABILIZED BY SALTS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-05-11 | — | — | US | disclosed |
| CN-110200903-B | Liquid formulations of amines and organic acids stabilized with salts | 武田药品工业株式会社 | 2022-07-29 | — | — | CN | disclosed |
| CN-113149883-A | Process for preparing azole compounds | 武田药品工业株式会社 | 2021-07-23 | — | — | CN | disclosed |
| CN-113121399-A | Process for preparing azole compounds | 武田药品工业株式会社 | 2021-07-16 | — | — | CN | disclosed |
| EP-2963019-B1 | METHOD FOR PRODUCING PYRIDINE-3-SULFONYL CHLORIDE | TAKEDA PHARMACEUTICALS CO (JP) | 2020-08-12 | — | — | EP | disclosed |
| US-20080139639-A1 | 3-amino(alkyl)-substituted pyrrole compounds such as N-methyl-1-[1-(phenylsulfonyl)-5-(3-thienyl)-1H-pyrrol-3-yl]methanamine; peptic ulcer, Zollinger-Ellison syndrome, gastritis, gastroesophageal reflux disease, gastric cancer, ulcer caused by non-steroidal anti-inflammatory agent (NSAID) use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-06-12 | — | — | US | disclosed |
| EP-1803709-A1 | PROTON PUMP INHIBITORS | Takeda Pharmaceutical Company Limited (JP) | 2007-07-04 | — | — | EP | disclosed |
| EP-1608639-A2 | NOVEL BICYCLIC UREA DERIVATIVES USEFUL IN THE TREATMENT OF CANCER AND OTHER DISORDERS | Bayer Pharmaceuticals Corporation (US) | 2005-12-28 | — | — | EP | disclosed |
| US-20050038031-A1 | Novel bicyclic urea derivatives useful in the treatment of cancer and other disorders | BAYER HEALTHCARE LLC | 2005-02-17 | — | — | US | disclosed |
| US-20040235829-A1 | Novel cyanopyridine derivatives useful in the treatment of cancer and other disorders | BAYER HEALTHCARE LLC | 2004-11-25 | — | — | US | disclosed |
| WO-2004078748-A2 | NOVEL BICYCLIC UREA DERIVATIVES USEFUL IN THE TREATMENT OF CANCER AND OTHER DISORDERS | BAYER PHARMACEUTICALS CORPORATION (US) | 2004-09-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050038031-A1 | Novel bicyclic urea derivatives useful in the treatment of cancer and other disorders | CCNC, UACA, SLC14A1 | CA1 4587/4885CA2 3960/4885CA9 3120/4885 |
| US-20040235829-A1 | Novel cyanopyridine derivatives useful in the treatment of cancer and other disorders | VHL, HCCS, CDK4 | CA1 4251/4885CA2 1411/4885CA9 2004/4885 |
| US-20080139639-A1 | 3-amino(alkyl)-substituted pyrrole compounds such as N-methyl-1-[1-(phenylsulfonyl)-5-(3-thienyl)-1H-pyrrol-3-yl]methanamine; peptic ulcer, Zollinger-Ellison syndrome, gastritis, gastroesophageal reflux disease, gastric cancer, ulcer caused by non-steroidal anti-inflammatory agent (NSAID) use | PTGER1, PTGER3, NR3C1 | CA1 4017/4885CA2 4187/4885CA9 4024/4885 |
| US-20230143246-A1 | LIQUID PREPARATIONS OF AMINES AND ORGANIC ACIDS STABILIZED BY SALTS | OTC, SLC38A7, SRI | CA1 3402/4885CA2 2375/4885CA9 1359/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.